FDA Brief

Warning letters Devices

FDA warning letter to

DSAART, LLC. dba Alpha Aesthetics

High riskIssued Nov 24, 2021Posted Dec 28, 2021Center for Devices and Radiological Health

FDA warned Alpha Aesthetics after inspection found unvalidated sterilization and manufacturing, poor complaint handling, and missed injury reports for silicone implants.

What happened

FDA inspected the firm’s medical device operations in Carson City, NV, from July 19, 2021 through August 5, 2021 and found silicone facial and body contouring implants made under quality-system (CGMP) violations. FDA found sterilization, curing, and packaging-seal processes were not validated; complaint investigations were incomplete; corrective action and nonconforming-product controls were inadequate; and the five-year shelf life was not adequately validated. FDA also found the firm did not submit required medical device reports (MDRs) for complaints involving swelling, chronic inflammation, seroma, fracture, and explantation.

What FDA found

  1. The firm had not validated sterilization, curing, or packaging-seal processes for its silicone implants.

    21 CFR 820.75(a)
  2. The firm’s complaint files lacked details, investigation records, and justifications for not investigating implant failures and injuries.

    21 CFR 820.198(a), (b), (e)
  3. A corrective and preventive action record did not assess whether a process error affected product or what caused it.

    21 CFR 820.100(a)
  4. The firm did not document evaluation and disposition of nonconforming gluteal and pectoral implant lots.

    21 CFR 820.90(a)
  5. The firm did not adequately validate its five-year shelf life for silicone implants.

    21 CFR 820.30(g)
  6. The firm failed to submit timely serious-injury and malfunction reports and its MDR procedure did not cover electronic submission.

    21 CFR 803.50(a)(1)-(2); 803.17(a)(3)

What FDA wants

FDA tells the firm to notify it in writing within 15 business days of steps taken to correct all violations, prevent recurrence, and include documentation and a timetable for any longer-term actions.

Who should pay attention

  • clinics and surgeons implanting silicone body implants
  • distributors or brands selling Alpha Aesthetics implants
  • quality teams at small medical device manufacturers with complaint and MDR duties

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk